Clinical Trial Update: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial assessing etrolizumab versus adalimumab and placebo in TNF-inhibitor-Naïve moderate-severe ulcerative colitis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Etrolizumab (etrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2021-03-05